GlassScriptPhysician profile
Todd D Brodie
NPI 1003880170
$6,630.50
in general payments reported to CMS, 2019-2025
44 companies · $1,326 in 2025
The $1,326 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,194 · 2020: $392 · 2021: $540 · 2022: $475 · 2023: $1,164 · 2024: $1,539 · 2025: $1,326.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,007 · Education: $22.20.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,006.83 |
| Education | $22.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $711.49 | 2019-2025 | Evenity, Tepezza, Repatha |
| Lilly USA, LLC | $604.37 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $547.54 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Xeris Pharmaceuticals, INC. | $477.26 | 2022-2024 | Recorlev, Keveyis, Gvoke Hypopen |
| Corcept Therapeutics | $416.20 | 2019-2025 | Korlym |
| Radius Health, INC. | $376.22 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $289.44 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $275.97 | 2021-2025 | |
| Horizon Therapeutics Plc | $246.87 | 2023 | Tepezza |
| Recordati_rare_diseases_inc. | $243.21 | 2022-2025 | Isturisa, Signifor Lar |
| Dexcom, INC. | $222.06 | 2019-2023 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Insulet Corporation | $171.82 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $168.40 | 2019-2021 | |
| Abbott Laboratories | $168.25 | 2022-2025 | Freestyle Libre 3 |
| Tandem Diabetes Care, INC. | $145.96 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Brodie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.